Department of Ophthalmology, Ajou University School of Medicine, 164 World Cup-Ro, Yeongtong-Gu, Suwon, 16499, Korea.
Special Study Module, Ajou University School of Medicine, Suwon, Korea.
Graefes Arch Clin Exp Ophthalmol. 2023 Jul;261(7):1793-1808. doi: 10.1007/s00417-022-05953-7. Epub 2023 Jan 4.
Abnormal hypercoagulability and increased thromboembolic risk are common in patients with coronavirus disease (COVID-19). COVID-19 has been suggested to cause retinal vascular damage, with several studies on COVID-19 patients with retinal vascular occlusions. We reviewed and investigated studies on retinal vascular occlusions in patients diagnosed with COVID-19 and in those vaccinated for COVID-19.
Studies that reported retinal vascular occlusion in COVID-19 patients or in vaccinated people were identified using the terms "retinal occlusion," together with "severe acute respiratory syndrome coronavirus 2", "SARS-CoV-2," "COVID-19," "coronavirus," and "vaccine," through systematic searches of PubMed and Google Scholar databases until January 7, 2022.
Thirteen cases of retinal artery occlusion (RAO) and 14 cases of retinal vein occlusion (RVO) were identified among patients diagnosed with COVID-19. Half of the patients with RAO or RVO revealed no systemic disorders except current or past COVID-19, and ocular symptoms were the initial presentation in five cases. Among patients with RAO, most presented with central RAO at 1-14 days of COVID-19 diagnosis, with abnormal coagulation and inflammatory markers. Among those with RVO, two-thirds presented with central RVO and one-third with RVO. Eleven cases with acute macular neuroretinopathy (AMN) and/or paracentral acute middle maculopathy (PAMM) were reported among patients with COVID-19, presenting scotoma resolved spontaneously in most cases. Among the 26 cases vaccinated with either mRNA or adenoviral vector vaccines for COVID-19 and presenting retinal vascular occlusions, there were more RVO cases than RAO cases, and ocular symptoms mostly occurred within 3 weeks after vaccination. One case presented bilateral AMN and PAMM after COVID-19 vaccination.
Retinal vascular occlusions might be a manifestation of COVID-19, although rare, especially in patients at risk of systemic hypercoagulability and thromboembolism. For COVID-19 vaccines, the causal relationship is controversial because there are few case reports of retinal vascular occlusions after COVID-19 vaccination.
异常的高凝状态和血栓栓塞风险增加是冠状病毒病(COVID-19)患者的常见现象。有研究表明 COVID-19 可导致视网膜血管损伤,并且有几项关于 COVID-19 合并视网膜血管阻塞患者的研究。我们回顾和调查了诊断为 COVID-19 的患者和接种 COVID-19 疫苗的患者的视网膜血管阻塞的研究。
通过系统检索 PubMed 和 Google Scholar 数据库,使用术语“视网膜闭塞”与“严重急性呼吸综合征冠状病毒 2”“SARS-CoV-2”“COVID-19”“冠状病毒”和“疫苗”相结合,直到 2022 年 1 月 7 日,确定报告 COVID-19 患者或接种疫苗人群中视网膜血管阻塞的研究。
在诊断为 COVID-19 的患者中发现 13 例视网膜动脉阻塞(RAO)和 14 例视网膜静脉阻塞(RVO)。除当前或既往 COVID-19 外,一半的 RAO 或 RVO 患者无系统疾病,5 例患者以眼部症状为首发表现。在 RAO 患者中,大多数在 COVID-19 诊断后 1-14 天出现中央 RAO,伴有异常凝血和炎症标志物。在 RVO 患者中,三分之二为中央 RVO,三分之一为 RVO。在 COVID-19 患者中报告了 11 例急性黄斑神经视网膜病变(AMN)和/或旁中心急性中黄斑病变(PAMM),大多数病例的视力障碍可自发缓解。在接种 mRNA 或腺病毒载体 COVID-19 疫苗并出现视网膜血管阻塞的 26 例患者中,RVO 病例多于 RAO 病例,眼部症状多发生在疫苗接种后 3 周内。1 例 COVID-19 疫苗接种后出现双侧 AMN 和 PAMM。
视网膜血管阻塞可能是 COVID-19 的一种表现,尽管罕见,但在有全身性高凝和血栓栓塞风险的患者中更为常见。对于 COVID-19 疫苗,因果关系存在争议,因为 COVID-19 疫苗接种后视网膜血管阻塞的病例报告很少。